Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Rani Therapeutics's Ustekinumab Biosimilar?
Ustekinumab Biosimilar is a monoclonal antibody commercialized by Rani Therapeutics, with a leading Phase I program in Psoriatic Arthritis. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Rani Therapeutics's Ustekinumab Biosimilar?
Ustekinumab Biosimilar is a monoclonal antibody commercialized by Rani Therapeutics, with a leading Phase I program in Psoriatic Arthritis. According...